Education
About Us
Working with TipRanks
Follow Us
Protalix Biotherapeutics (PLX)
:PLX
Earnings Data
Report Date
Aug 18, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.11Last Year’s EPS
-0.03Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 09, 2025
|% Change Since: 29.02%
|Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive and negative aspects. The company showcased substantial revenue growth, promising developments in its pipeline, and a strong cash position. However, these were counterbalanced by increased costs associated with goods sold and R&D, alongside a continued net loss. The sentiment of the call is balanced.Company Guidance
During the Protalix BioTherapeutics First Quarter 2025 Financial and Business Results Conference Call, the company reported a 70% increase in revenues from selling goods, reaching $10 million for the quarter ending March 31, 2025, compared to $3.7 million in the same period the previous year. This increase was driven primarily by a $5.9 million uptick in sales to Pfizer and an additional $400,000 in sales to Fircruz in Brazil. Despite the revenue growth, the cost of goods sold also rose by 215% to $8.2 million. Research and development expenses increased by 21% to $3.5 million, reflecting ongoing advancements in their clinical pipeline. The company also highlighted their cash position, with cash, cash equivalents, and short-term bank deposits totaling approximately $34.7 billion as of March 31, 2025. Looking forward, Protalix BioTherapeutics aims to initiate a phase two clinical trial for PRX-115 later in the year and is working closely with Chiesi Global Rare Diseases on the potential approval of a reduced dosing frequency for their Fabry disease treatment by the European Medicines Agency.Significant Revenue Growth
Revenues from selling goods increased by 70% to $10 million in Q1 2025 compared to $3.7 million in Q1 2024. This was primarily driven by a $5.9 million increase in sales to Pfizer and a $400,000 increase in sales to Fircruz in Brazil.
Positive Developments for PRX-115
Encouraging results from the first in human study of PRX-115, showing increased exposure and a rapid reduction in plasma uric acid levels in a dose-dependent manner. Plans to initiate a phase two clinical trial for PRX-115 in gout patients later this year.
Reduction in Operating Expenses
Selling, general, and administrative expenses decreased by 16% to $2 million in Q1 2025 from $3.1 million in Q1 2024, primarily due to a decrease in salary-related expenses and selling expenses.
Cash Position
Cash, cash equivalents, and short-term bank deposits were approximately $34.7 billion as of March 31, 2025.
---
PLX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PLX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 17, 2025 | $2.24 | $2.45 | +9.37% |
| Nov 14, 2024 | $1.24 | $1.41 | +13.71% |
| Aug 14, 2024 | $1.04 | $0.93 | -10.58% |
| May 10, 2024 | $1.25 | $1.10 | -12.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Protalix Biotherapeutics (PLX) report earnings?
Protalix Biotherapeutics (PLX) is schdueled to report earning on Aug 18, 2025, TBA Not Confirmed.
What is Protalix Biotherapeutics (PLX) earnings time?
Protalix Biotherapeutics (PLX) earnings time is at Aug 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PLX EPS forecast?
PLX EPS forecast for the fiscal quarter 2025 (Q2) is 0.11.
---